JP7480454B2 - 有効成分として間葉系幹細胞を含む炎症性疾患の予防又は治療のための医薬組成物 - Google Patents
有効成分として間葉系幹細胞を含む炎症性疾患の予防又は治療のための医薬組成物 Download PDFInfo
- Publication number
- JP7480454B2 JP7480454B2 JP2020564579A JP2020564579A JP7480454B2 JP 7480454 B2 JP7480454 B2 JP 7480454B2 JP 2020564579 A JP2020564579 A JP 2020564579A JP 2020564579 A JP2020564579 A JP 2020564579A JP 7480454 B2 JP7480454 B2 JP 7480454B2
- Authority
- JP
- Japan
- Prior art keywords
- stem cells
- mesenchymal stem
- hla
- disease
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims description 138
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 22
- 208000027866 inflammatory disease Diseases 0.000 title claims description 16
- 239000004480 active ingredient Substances 0.000 title claims description 6
- 210000004700 fetal blood Anatomy 0.000 claims description 19
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims description 12
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims description 9
- 102100037241 Endoglin Human genes 0.000 claims description 9
- 102100024210 CD166 antigen Human genes 0.000 claims description 8
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 8
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 claims description 8
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims description 7
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 7
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 7
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 7
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 7
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 6
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 6
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 206010003645 Atopy Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 46
- 241000699670 Mus sp. Species 0.000 description 23
- 206010061218 Inflammation Diseases 0.000 description 16
- 230000004054 inflammatory process Effects 0.000 description 16
- 230000003110 anti-inflammatory effect Effects 0.000 description 12
- 238000010172 mouse model Methods 0.000 description 12
- 210000005013 brain tissue Anatomy 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 11
- 229920006008 lipopolysaccharide Polymers 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 206010058490 Hyperoxia Diseases 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000028709 inflammatory response Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000008157 ELISA kit Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000003193 general anesthetic agent Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011818 5xFAD mouse Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 239000012979 RPMI medium Substances 0.000 description 3
- 230000008382 alveolar damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 238000007914 intraventricular administration Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 231100000516 lung damage Toxicity 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010036395 Endoglin Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000011786 HLA-A Antigens Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 2
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 2
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 2
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000222 hyperoxic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 2
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229940069575 rompun Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 101150014309 ALCAM gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100021723 Arginase-1 Human genes 0.000 description 1
- 101710129000 Arginase-1 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101150118155 Cd34 gene Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101150101087 Nt5e gene Proteins 0.000 description 1
- 101150071454 PTPRC gene Proteins 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007040 lung development Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Gastroenterology & Hepatology (AREA)
Description
臍帯血由来間葉系幹細胞については、間葉系幹細胞を最初に臍帯血から単離し、次に5回継代した。継代された間葉系幹細胞(5回継代)は、いくつかのロットで使用されるように液体窒素中で凍結保存した。凍結保存した間葉系幹細胞は、37℃の恒温水浴中で約3分間解凍した。次に、間葉系幹細胞を10%(v/v)ウシ胎児血清(FBS)を含有するα-MEM培地に再懸濁し、遠心分離機で1200rpmで5分間遠心分離した。遠心分離が完了した後、上清を除去し、残存する間葉系幹細胞をリン酸緩衝生理食塩水(PBS)に再懸濁した。
HLA-A2発現に応じた間葉系幹細胞の炎症抑制効力を比較するために、各ロットにおける間葉系幹細胞の炎症抑制効果を調べた。
間葉系幹細胞におけるHLA-A2の発現を抑制した場合も間葉系幹細胞の抗炎症効果の抑制をもたらすかどうかを確認するために、炎症抑制効果を比較用するため、siRNAを使用して間葉系幹細胞におけるHLA-A2の発現を抑制した。
臍帯血由来間葉系幹細胞におけるHLA-A2の発現が臍帯血由来間葉系幹細胞の継代数に応じて変化するかどうかを確認するために、間葉系幹細胞を最初に臍帯血から単離し、次に2回継代した間葉系幹細胞(2代目、P2、G028)及び6回継代した間葉系幹細胞(6代目、P6、G171)を使用してHLA-A2発現パターンを分析した。
気管支肺異形成症は、肺構造の異常及び肺発達の停止を特徴とする疾患である。これは、呼吸窮迫の新生児に酸素換気装置による高濃度酸素療法を適用する過程で、肺の炎症が過度に誘発され肺障害を引き起こす、炎症性疾患の1つである。今のところ、世界中において、気管支肺異形成症の根本的治療や治療法はない。
アルツハイマー病マウスモデルとして、6か月齢5XFADマウス(Jackson Laboratory、米国)を使用した。5XFADマウスでは、2か月齢からアミロイドベータが脳組織で産生され始め、4か月齢でアミロイドベータは脳組織に蓄積し、約6か月齢で認知障害が現れる。6月齢5XFADマウスに、マウスの体重(g)あたり5μlの麻酔薬を腹腔内投与し、使用した麻酔薬は、ゾレチル、ロンプン及び生理食塩水を4:1:5の比で混合したものである。
Claims (4)
- 活性成分として、間葉系幹細胞の集団を含み、前記間葉系幹細胞の集団が臍帯血に由来し、前記集団において、表面にHLA-A2を発現している間葉系幹細胞が70%以上である、炎症性疾患を予防又は治療するための医薬組成物。
- 前記集団において、表面にCD73、CD90、CD105及びCD166のそれぞれを発現している間葉系幹細胞が70%以上であり、CD14、CD34、CD45及びHLA-DRのそれぞれを発現している間葉系幹細胞が1%以下である、請求項1に記載の医薬組成物。
- 前記集団において、表面にHLA-A2を発現している間葉系幹細胞が75%以上であり、CD73、CD90、CD105及びCD166のそれぞれを発現している間葉系幹細胞が70%以上であり、CD14、CD34、CD45及びHLA-DRのそれぞれを発現している間葉系幹細胞が1%以下である、請求項1に記載の医薬組成物。
- 前記炎症性疾患が、関節リウマチ、アトピー、喘息、アレルギー性鼻炎、アルツハイマー病、移植片対宿主病(GVHD)、糖尿病性腎症、クローン病、炎症性腸疾患、移植後の拒絶反応、気管支肺異形成症(BPD)又は慢性閉塞性肺疾患(COPD)である、請求項1~3のいずれか一項に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862680748P | 2018-06-05 | 2018-06-05 | |
US62/680,748 | 2018-06-05 | ||
PCT/KR2019/006817 WO2019235854A1 (ko) | 2018-06-05 | 2019-06-05 | 간엽줄기세포를 유효성분으로 포함하는 염증 질환 예방 또는 치료용 약학 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021526135A JP2021526135A (ja) | 2021-09-30 |
JP7480454B2 true JP7480454B2 (ja) | 2024-05-10 |
Family
ID=68769796
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020564579A Active JP7480454B2 (ja) | 2018-06-05 | 2019-06-05 | 有効成分として間葉系幹細胞を含む炎症性疾患の予防又は治療のための医薬組成物 |
JP2020564727A Active JP7343091B2 (ja) | 2018-06-05 | 2019-06-05 | 軟骨損傷関連の疾患を処置するための、ヒアルロン酸及び幹細胞を含む医薬組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020564727A Active JP7343091B2 (ja) | 2018-06-05 | 2019-06-05 | 軟骨損傷関連の疾患を処置するための、ヒアルロン酸及び幹細胞を含む医薬組成物 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20210228636A1 (ja) |
EP (2) | EP3811951A4 (ja) |
JP (2) | JP7480454B2 (ja) |
KR (2) | KR20210008101A (ja) |
CN (2) | CN112261944A (ja) |
AU (2) | AU2019283518A1 (ja) |
CA (2) | CA3100466A1 (ja) |
SG (2) | SG11202011927TA (ja) |
WO (2) | WO2019235854A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202011927TA (en) * | 2018-06-05 | 2020-12-30 | Medipost Co Ltd | Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease |
KR20220152137A (ko) | 2021-05-07 | 2022-11-15 | 의료법인 성광의료재단 | 골 분화능 기능강화 중간엽 줄기세포 및 이의 용도 |
CN113616675A (zh) * | 2021-08-23 | 2021-11-09 | 上海太安堂生物医学有限公司 | 含间充质干细胞的组合物及其在治疗退行性关节炎的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007530543A (ja) | 2004-03-22 | 2007-11-01 | オシリス セラピューティクス,インコーポレイテッド | 間葉幹細胞及びその使用法 |
JP2015071559A (ja) | 2013-10-02 | 2015-04-16 | 日本製薬株式会社 | Il−17産生抑制組成物 |
JP2017520583A (ja) | 2014-06-30 | 2017-07-27 | ティジェニクス エス.エー.ユー. | 全身性炎症反応症候群の治療のための間葉系間質細胞 |
WO2018083700A1 (en) | 2016-11-03 | 2018-05-11 | Exostem Biotec Ltd. | Mesenchymal stem cells populations, their products, and use thereof |
JP2018513388A (ja) | 2015-04-24 | 2018-05-24 | ティジェニクス エス.エー.ユー. | 細胞療法に対する臨床応答を決定するためのバイオマーカー |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1416944B1 (en) * | 2001-08-14 | 2005-12-14 | Medipost, Co., Ltd. | Composition for treatment of articular cartilage damage |
EP1627047A4 (en) * | 2003-05-07 | 2008-07-16 | Jolla Inst For Molecular Medic | METHODS FOR FACILITATING RECOVERY OF FUNCTIONS OF ENDOGENOUS, IMPLANTED OR TRANSPLANTED STEM CELLS BY MEANS OF HYALURONIC ACID OF HIGH MOLECULAR WEIGHT |
AU2005228778B2 (en) | 2004-03-31 | 2010-04-01 | Yukio Kato | Therapeutic agents and therapeutic methods for treating injured tissue |
ES2528272T3 (es) * | 2005-12-07 | 2015-02-06 | Isto Technologies Inc. | Métodos de reparación de cartílago |
US20070178073A1 (en) * | 2006-02-01 | 2007-08-02 | Samsung Life Public Welfare Foundation | Composition Comprising Separated or Proliferated Cells from Umbilical Cord Blood for Treating Developmental and/or Chronic Lung Disease |
EP2630959A1 (en) * | 2007-02-12 | 2013-08-28 | Anthrogenesis Corporation | Treatment of inflammatory diseases using placental stem cells |
WO2008144820A1 (en) * | 2007-05-28 | 2008-12-04 | Monash University | Treatment of chronic lung disease |
AU2009214044B2 (en) * | 2008-02-15 | 2014-08-14 | Bone Therapeutics | Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases |
WO2011126177A1 (ko) * | 2010-04-05 | 2011-10-13 | 서울대학교병원 | 인간 줄기세포의 활성을 증가시키는 방법 |
CN103263440A (zh) * | 2013-02-08 | 2013-08-28 | 周胜利 | 从胎盘、脐带中提、制同源性间充质干细胞注射剂的方法 |
WO2015022670A1 (en) | 2013-08-14 | 2015-02-19 | Stempeutics Research Pvt. Ltd. | Management of osteoarthritis using pooled allogeneic mesenchymal stem cells |
US20170166869A1 (en) * | 2014-02-04 | 2017-06-15 | Jose Javier Lopez GONZALEZ | Biologically optimized adult mesenchymal stem cells |
GB201410504D0 (en) * | 2014-06-12 | 2014-07-30 | Cell Therapy Ltd | Immuno-modulaltory progenitor (IMP) cell |
KR101779763B1 (ko) * | 2015-03-04 | 2017-09-19 | 메디포스트(주) | 증식력 및 분화능이 개선된 간엽줄기세포를 포함하는 폐질환 예방 또는 치료용 약학적 조성물 |
CN104840486A (zh) * | 2015-04-30 | 2015-08-19 | 北京益诺勤生物技术有限公司 | 一种组合物及其应用、制剂 |
HUP1500218A2 (hu) * | 2015-05-08 | 2016-11-28 | Deltabio 2000 Kft | Eljárás és készítmény ortopédiai betegségek, így ízületiporc-sérülések, különösen ízületi diszplázia kezelésére |
EP3097922A1 (fr) | 2015-05-28 | 2016-11-30 | Denis Barritault | Composition pour le traitement des lesions tissulaires |
WO2017147649A1 (en) | 2016-02-29 | 2017-09-08 | Magellan Stem Cells Pty Ltd | Methods of treatment |
CN105796600B (zh) * | 2016-04-28 | 2020-02-28 | 博雅干细胞科技有限公司 | 使用干细胞治疗骨关节炎的方法和组合物 |
US20180021380A1 (en) * | 2016-07-21 | 2018-01-25 | Sungkwang Medical Foundation | Composition including mesenchymal stem cell derived from adipose tissues and hyaluronic acid derivative, method of preparing the same, and method of preventing or treating low back pain using the same |
ES2927406T3 (es) * | 2016-10-24 | 2022-11-04 | United Therapeutics Corp | Potenciación de las propiedades inmunomoduladoras de las MSC mediante treprostinil |
WO2018185584A1 (en) * | 2017-04-05 | 2018-10-11 | Pluristem Ltd. | Methods and compositions for treating acute lung injury and respiratory distress syndrome |
SG11202011927TA (en) * | 2018-06-05 | 2020-12-30 | Medipost Co Ltd | Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease |
CN111518758A (zh) * | 2020-04-30 | 2020-08-11 | 深圳市合一康生物科技股份有限公司 | 一种用于肺病治疗的脐带间充质干细胞及其制备方法 |
CN113018317A (zh) * | 2021-02-03 | 2021-06-25 | 上海兰天生物医药科技有限公司 | 间充质干细胞联合玻璃酸钠在治疗关节炎中的应用 |
-
2019
- 2019-06-05 SG SG11202011927TA patent/SG11202011927TA/en unknown
- 2019-06-05 AU AU2019283518A patent/AU2019283518A1/en active Pending
- 2019-06-05 JP JP2020564579A patent/JP7480454B2/ja active Active
- 2019-06-05 KR KR1020207036315A patent/KR20210008101A/ko not_active Application Discontinuation
- 2019-06-05 JP JP2020564727A patent/JP7343091B2/ja active Active
- 2019-06-05 CA CA3100466A patent/CA3100466A1/en active Pending
- 2019-06-05 US US16/972,118 patent/US20210228636A1/en active Pending
- 2019-06-05 CN CN201980038790.3A patent/CN112261944A/zh active Pending
- 2019-06-05 EP EP19814590.6A patent/EP3811951A4/en active Pending
- 2019-06-05 WO PCT/KR2019/006817 patent/WO2019235854A1/ko unknown
- 2019-06-05 KR KR1020207036318A patent/KR20210008873A/ko not_active Application Discontinuation
- 2019-06-05 WO PCT/KR2019/006816 patent/WO2019235853A1/ko unknown
- 2019-06-05 CN CN201980038809.4A patent/CN112261943A/zh active Pending
- 2019-06-05 CA CA3100471A patent/CA3100471A1/en active Pending
- 2019-06-05 EP EP19815851.1A patent/EP3804736A4/en active Pending
- 2019-06-05 SG SG11202012124PA patent/SG11202012124PA/en unknown
- 2019-06-05 US US16/972,373 patent/US20210228637A1/en active Pending
- 2019-06-05 AU AU2019283517A patent/AU2019283517A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007530543A (ja) | 2004-03-22 | 2007-11-01 | オシリス セラピューティクス,インコーポレイテッド | 間葉幹細胞及びその使用法 |
JP2015071559A (ja) | 2013-10-02 | 2015-04-16 | 日本製薬株式会社 | Il−17産生抑制組成物 |
JP2017520583A (ja) | 2014-06-30 | 2017-07-27 | ティジェニクス エス.エー.ユー. | 全身性炎症反応症候群の治療のための間葉系間質細胞 |
JP2018513388A (ja) | 2015-04-24 | 2018-05-24 | ティジェニクス エス.エー.ユー. | 細胞療法に対する臨床応答を決定するためのバイオマーカー |
WO2018083700A1 (en) | 2016-11-03 | 2018-05-11 | Exostem Biotec Ltd. | Mesenchymal stem cells populations, their products, and use thereof |
Non-Patent Citations (1)
Title |
---|
Stem Cells,2008年,Vol.26, No.5,pp.1275-1287 |
Also Published As
Publication number | Publication date |
---|---|
CA3100471A1 (en) | 2019-12-12 |
EP3811951A4 (en) | 2022-07-13 |
CN112261943A (zh) | 2021-01-22 |
KR20210008873A (ko) | 2021-01-25 |
EP3811951A1 (en) | 2021-04-28 |
JP2021526137A (ja) | 2021-09-30 |
CN112261944A (zh) | 2021-01-22 |
JP2021526135A (ja) | 2021-09-30 |
EP3804736A4 (en) | 2022-03-30 |
US20210228637A1 (en) | 2021-07-29 |
CA3100466A1 (en) | 2019-12-12 |
JP7343091B2 (ja) | 2023-09-12 |
SG11202012124PA (en) | 2021-01-28 |
WO2019235853A1 (ko) | 2019-12-12 |
AU2019283517A1 (en) | 2021-01-21 |
US20210228636A1 (en) | 2021-07-29 |
EP3804736A1 (en) | 2021-04-14 |
SG11202011927TA (en) | 2020-12-30 |
WO2019235854A1 (ko) | 2019-12-12 |
AU2019283518A1 (en) | 2021-01-14 |
KR20210008101A (ko) | 2021-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7480454B2 (ja) | 有効成分として間葉系幹細胞を含む炎症性疾患の予防又は治療のための医薬組成物 | |
JP6190536B2 (ja) | 幹細胞由来のエキソソームを有効成分に含む脳室内出血治療用薬学的組成物 | |
CN110088623B (zh) | 选择用于治疗免疫病症的高效干细胞的方法 | |
Kim et al. | Amniotic mesenchymal stem cells have robust angiogenic properties and are effective in treating hindlimb ischaemia | |
Wang et al. | Depletion of microglia attenuates dendritic spine loss and neuronal apoptosis in the acute stage of moderate traumatic brain injury in mice | |
BRPI0919020B1 (pt) | Uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris | |
KR102198943B1 (ko) | 뇌신경계 질환의 치료 또는 진단을 위한 표적 단백질로서 pcnt | |
JP7168653B2 (ja) | 間葉系幹細胞を含む甲状腺眼症を治療するための組成物 | |
US20240287462A1 (en) | Use of Toll-Like Receptor 4 Agonists to Treat Inflammation and Tissue Injury | |
Priya et al. | Brain astrocytes and microglia express functional MR1 molecules that present microbial antigens to mucosal-associated invariant T (MAIT) cells | |
Lim et al. | Ex vivo generated human cord blood myeloid-derived suppressor cells attenuate murine chronic graft-versus-host diseases | |
DK2790712T3 (en) | Human monocyte subpopulation FOR THE TREATMENT OF DAMAGE TO THE CENTRAL NERVOUS SYSTEM | |
JP7255805B2 (ja) | 多能性幹細胞による胎児発育不全に伴う脳障害の改善及び治療 | |
US20220175842A1 (en) | Exosomes and uses thereof in diseases of the brain | |
JP6994200B2 (ja) | 多能性幹細胞による周産期脳障害の改善及び治療 | |
JP7165352B2 (ja) | 多能性幹細胞による慢性肺疾患の改善及び治療 | |
US20200353007A1 (en) | Pharmacological Composition for Prevention or Treatment of Lupus, Comprising Mesenchymal Stem Cell-Derived Secretome | |
US20160206699A1 (en) | Use of interleukin 10 mrna transfected macrophages in anti-inflammatory therapies | |
EP3493835A1 (en) | Method for ex vivo induction of suppressor lymphocytes using a solution of proteins from helminth parasites, lymphocytes produced by this method and uses thereof | |
US20220160777A1 (en) | Method for treating atopic dermatitis using monoclonal stem cells | |
US20120315246A1 (en) | Compositions and methods for modulating inflammatory and/or immune responses | |
Yuan et al. | CCR5-overexpressing mesenchymal stem cells protect against experimental autoimmune uveitis: insights from single-cell transcriptome analysis | |
WO2024210859A1 (en) | Use of embryonated toxocara canis eggs inactivated by different methods as a drug candidate | |
JP2023510512A (ja) | 神経変性障害を治療するための間葉系幹細胞を含む組成物 | |
Bordet et al. | Elisa Crisci5, 6, Mathieu Tiret5, Delphyne Descamps1, Cindy Bernelin-Cottet1, Céline Urien1, François Lefèvre1, Luc Jouneau1, Olivier Bourry2, 3, Jean-Jacques Leplat5, Isabelle Schwartz-Cornil1 & Nicolas Bertho1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201119 Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201118 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20201118 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220325 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230328 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230612 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230821 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240207 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240326 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240402 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7480454 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |